Cannabis Victims Group Takes Rescheduling Fight to Federal Appeals Court

A coalition of cannabis industry victims has escalated its legal challenge against federal marijuana rescheduling, filing an appeal with the United States Court of Appeals for the D.C. Circuit that could reshape the regulatory debate around cannabis classification.

Cannabis Industry Victims Educating Litigators (CIVEL)—an organization representing individuals who claim harm from marijuana use—is challenging the Drug Enforcement Administration's proposed move to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act.

The appeal represents a significant counter-narrative to the industry's push for rescheduling. While most cannabis advocates view the DEA's proposal as progress toward normalization, CIVEL's litigation argues the move doesn't adequately address public health concerns or regulatory oversight.

The Legal Challenge

The D.C. Circuit will now determine whether the DEA's rescheduling process meets federal regulatory standards. The numbers tell the story: Schedule III classification would maintain cannabis as a controlled substance while acknowledging accepted medical use and lower abuse potential than Schedule I drugs like heroin.

But CIVEL's challenge focuses on what they characterize as regulatory failure—arguing the rescheduling process hasn't properly evaluated the substance's risks or established appropriate safeguards. The organization has positioned itself as a watchdog against what it views as insufficient federal oversight of an expanding cannabis market.

Market watchers note the timing is crucial. The DEA's rescheduling proposal, announced after a comprehensive Health and Human Services review, has already triggered billions in market capitalization gains for publicly traded cannabis companies. Yet this legal challenge could delay or derail the entire process.

Industry Response

The cannabis industry has largely dismissed opposition to rescheduling as prohibitionist rhetoric. But CIVEL's approach differs from traditional anti-legalization groups by focusing on regulatory adequacy rather than blanket opposition.

The organization's members include individuals who report adverse experiences with cannabis products—a demographic rarely represented in policy debates dominated by industry advocates and reform organizations.

This creates an unusual dynamic: The industry wants rescheduling to proceed for tax relief and banking access, while CIVEL argues the process itself is flawed regardless of the outcome.

What's at Stake

Schedule III status would eliminate the 280E tax provision that prevents cannabis businesses from deducting ordinary business expenses. Industry analysts estimate this change could save major operators $100 million or more annually.

But the D.C. Circuit could rule several ways. The court might uphold the DEA's process, reject it entirely, or send it back for additional review—each outcome carrying different implications for the $30 billion legal cannabis market.

The case also tests whether federal agencies have properly balanced competing interests: medical research, public health concerns, state-level legalization, and industry development.

The Road Ahead

Appellate proceedings typically take months, meaning resolution likely won't come until late 2025 at the earliest. During that time, cannabis remains Schedule I—maintaining the status quo for federal enforcement, banking restrictions, and tax treatment.

CIVEL's challenge adds complexity to what many assumed would be a straightforward administrative process. The organization's ability to demonstrate standing and convince a federal appeals court that regulatory failures occurred will determine whether this becomes a footnote or a major obstacle to rescheduling.

For now, the cannabis industry faces continued uncertainty. Companies have already priced in potential rescheduling benefits, making any delay or reversal a significant market risk. And the debate over cannabis regulation continues to reveal deep divisions over how—or whether—to integrate the plant into federal drug policy.

The D.C. Circuit's eventual ruling will either clear the path for historic rescheduling or force regulators back to the drawing board.

---

This article is based on original reporting by www.morningstar.com.